<DOC>
	<DOCNO>NCT00564759</DOCNO>
	<brief_summary>The aim study evaluate side effect risk infusion retroviral gene correct autologous CD34+ cell peripheral blood chemotherapy condition ( busulphan ) patient chronic granulomatous disease ( CGD ) . Also gene correct functional active granulocyte peripheral blood engraftment bone marrow patient monitor document .</brief_summary>
	<brief_title>Gene Therapy Chronic Granulomatous Disease</brief_title>
	<detailed_description />
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>xlinked Chronic Granulomatous Disease history lifethreatening severe infection HLAmatched related nonrelated donor therapy resistent life threaten infections/organ dysfunction treatment option e.g . BMT &lt; 18 year age HIV infection life expectancy &gt; 2 year infection treatable conventional therapy ( antibiotic , allogeneic granulocyte )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>CGD</keyword>
</DOC>